Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alaska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alaska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alaska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Ryan Ragle (NPI 1073781951)

Field	Value
Entity Type	Individual
Organization	Ryan Ragle
Address	3801 Lake Otis Pkwy Ste 300
City	Anchorage
State	AK
ZIP	99508
Taxonomy	Rheumatology Physician
NPI Enumerated	February 13, 2008

Payer Source	Total Paid
Medicare	$413.8K
Medicaid	$0

Key Findings

This provider’s billing footprint is effectively single‑payer: all reported public claims are Medicare revenue of $413.8K and there is no Medicaid billing on file. The absence of any Medicaid activity signals limited Medicaid exposure and means analyses should treat this practice as Medicare‑centric rather than dual‑payer when assessing payer mix or access to state‑funded populations.

Revenue is highly concentrated in a small set of services: the precomputed top three Medicare codes (J1745, J3111, 99214) together account for 75.3% of total Medicare revenue. That concentration indicates the practice’s economics are driven primarily by a mix of biologic injectable therapy reimbursement and established outpatient evaluation & management encounters.

The specific code mix points to an infusion/injection‑oriented rheumatology practice. Dominant codes J1745 (infliximab) and J3111 (romosozumab) are high‑revenue injectable biologics, and the high share of 99214 (established E&M visits) shows substantial clinic visit volume tied to ongoing management and biologic administration.

Competitive standing versus national Medicare peers is mixed across the top codes: J1745 ranks #350 of 1352 (74th percentile; typical, unremarkable volume for this code) and J3111 ranks #539 of 970 (44th percentile; typical, unremarkable volume for this code), indicating modest‑to‑moderate participation in biologic administration. By contrast, 99214 ranks #37719 of 479517 (92th percentile; typical, unremarkable volume for this code), reflecting relatively strong E&M throughput versus peers and a heavier established‑patient workload.

Secondary therapy and infusion activity also appear in the revenue mix: J0897 (denosumab) represents 13.0% of Medicare revenue and 96413 (chemotherapy/infusion administration) contributes 4.5%. These codes reinforce that the practice bills for in‑office injectable/infusion therapies beyond just the two top biologics, supporting an operational model that combines procedural administration with clinic management.

Ancillary services and monitoring are present at modest levels, with frequent lab and collection codes such as 80053, 85025, 36415, 86140, and 85651 appearing on the top list. This pattern is consistent with chronic rheumatologic care where routine lab monitoring and phlebotomy are part of longitudinal patient management and therapy safety checks.

The provider has a long tenure in the Medicare program, with NPI enumeration dated 2008-02-13 (~18 years ago), which suggests an established practice and potential ongoing referral relationships in the market. Longevity combined with concentrated biologic administration and high E&M volume implies an operationally mature rheumatology clinic rather than a recently opened or transient billing entity.

From a payer and contracting perspective, the combination of concentrated Medicare revenue and no Medicaid billing represents both a strength and a vulnerability: the practice appears efficient at capturing Medicare biologic and follow‑up visit revenue but has no recorded Medicaid presence, which may limit negotiating leverage for state Medicaid contracts or leave growth opportunities in public plans unexplored.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

20 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J1745	Injection, infliximab, excludes biosimilar, 10 mg	5,220	$30	$135.7K
J3111	Injection, romosozumab-aqqg, 1 mg	13,860	$10	$110.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	580	$110	$62.7K
J0897	Injection, denosumab, 1 mg	2,820	$20	$53.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	170	$110	$18.6K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	30	$140	$3.6K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	60	$50	$3.2K
99205	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider…	10	$210	$2.7K
80053	The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel.	270	$10	$2.7K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	10	$180	$2.5K

Showing 1–10 of 20

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 20 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alaska Distribution

Ryan Ragle — 3 of 20 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alaska

Full comparison — all codes billed, vs. state median

20 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J1745	2	10	5,220	$30	$235K
J3111	4	10	22,470	$10	$192.9K
J0897	15	30	2,700	$20	$82.7K
96413	15	20	230	$110	$30.2K
99214	46	1,210	90	$100	$16.2K
99215	356	400	40	$150	$11K
99213	1,004	1,290	70	$70	$8.5K
99205	118	140	30	$190	$7.4K
99204	253	460	30	$140	$6.1K
96365	14	30	70	$50	$4.8K

Showing 1–10 of 20

Related Providers

Other providers that share a Tax Identification Number (TIN) with Ryan Ragle, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Orthoalaska, LLC	AK	Orthopaedic Surgery Physician	$0	$5.8M
John Botson	AK	Rheumatology Physician	$1.8M	$0
Amikar Sehdev	AZ	Hematology & Oncology Physician	$641K	$0
Bryan Haughom	AK	Orthopaedic Surgery Physician	$525.6K	$0
Laura Luebke	AK	Medical Physician Assistant	$428.6K	$0
James Eule	AK	Orthopaedic Surgery of the Spine Physician	$400.6K	$0
Mark Flanum	AK	Orthopaedic Surgery of the Spine Physician	$270K	$0
Derrick Foge	AK	Orthopaedic Surgery of the Spine Physician	$268.1K	$0
Thomas Paynter	AK	Orthopaedic Surgery Physician	$260.9K	$0
Curtis Mina	AK	Orthopaedic Surgery of the Spine Physician	$236.4K	$0

Ryan Ragle — Billing Profile & Reimbursement Data

Sign up for Ryan Ragle — Billing Profile & Reimbursement Data policy alerts

Ryan Ragle — Billing Profile & Reimbursement Data

Sign up for Ryan Ragle — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Frequently Asked Questions

References